Currently, there are 90.08M common shares owned by the public and among those 87.44M shares have been available to trade.
The company’s stock has a 5-day price change of -6.67% and 1.45% over the past three months. IMUX shares are trading -6.67% year to date (YTD), with the 12-month market performance up to 19.66% higher. It has a 12-month low price of $0.95 and touched a high of $2.11 over the same period. IMUX has an average intraday trading volume of 382.19K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.51%, -7.53%, and 4.75% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Immunic Inc (NASDAQ: IMUX) shares accounts for 60.01% of the company’s 90.08M shares outstanding.
It has a market capitalization of $126.11M and a beta (3y monthly) value of 1.85. The earnings-per-share (ttm) stands at -$1.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.63% over the week and 8.40% over the month.
Earnings per share for the fiscal year are expected to increase by 56.87%, and 22.71% over the next financial year. EPS should shrink at an annualized rate of 15.50% over the next five years, compared to 31.12% over the past 5-year period.
Looking at the support for the IMUX, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on September 09, 2024, with the firm’s price target at $5. B. Riley Securities coverage for the Immunic Inc (IMUX) stock in a research note released on August 27, 2024 offered a Buy rating with a price target of $6. SVB Leerink was of a view on October 21, 2022 that the stock is Mkt Perform, while H.C. Wainwright gave the stock Buy rating on September 19, 2022, issuing a price target of $26. Aegis Capital on their part issued Buy rating on April 15, 2021.
